

# CITATION REPORT

List of articles citing

Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE

DOI: 10.1136/lupus-2018-000263

Lupus Science and Medicine, 2018, 5, e000263.

**Source:** <https://exaly.com/paper-pdf/71755692/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
17	Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity. <i>Lupus</i> , <b>2018</b> , 27, 2262-2268	3.6	7
16	Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE. <i>Lupus Science and Medicine</i> , <b>2019</b> , 6, e000318	4.6	23
15	Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 773	8.4	14
14	Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 78-88	9.5	21
13	Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties. <i>Rheumatology</i> , <b>2020</b> , 59, 3622-3632	3.9	8
12	Cell-bound complement activation products associate with lupus severity in SLE. <i>Lupus Science and Medicine</i> , <b>2020</b> , 7,	4.6	4
11	Distinguishing lupus lymphadenitis from Kikuchi disease based on clinicopathological features and C4d immunohistochemistry. <i>Rheumatology</i> , <b>2021</b> , 60, 1543-1552	3.9	2
10	Systemic lupus erythematosus: The search for the ideal biomarker. <i>Lupus</i> , <b>2021</b> , 30, 181-203	2.6	7
9	A Review of Complement Activation in SLE. <i>Current Rheumatology Reports</i> , <b>2021</b> , 23, 16	4.9	14
8	Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus. <i>Biomolecules</i> , <b>2021</b> , 11,	5.9	5
7	Platelet bound complement split product (PC4d) is a marker of platelet activation and arterial vascular events in Systemic Lupus Erythematosus. <i>Clinical Immunology</i> , <b>2021</b> , 228, 108755	9	2
6	Use of Physician Global Assessment (PGA) in Systemic lupus erythematosus: a systematic review of its psychometric properties.		2
5	Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome. <i>Hematology American Society of Hematology Education Program</i> , <b>2019</b> , 2019, 415-420	3.1	2
4	Data_Sheet_1.docx. <b>2019</b> ,		
3	Physician Global Assessment International Standardisation CONsensus in Systemic Lupus Erythematosus: the PISCOS study. <i>Lancet Rheumatology</i> , <b>2022</b> ,	14.2	2
2	Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) in the prediction of poor pregnancy outcomes in systemic lupus erythematosus (SLE). <b>2022</b> , 9, e000754		0
1	Complement as a Biomarker for Systemic Lupus Erythematosus. <b>2023</b> , 13, 367		0

